Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mantle cell lymphoma.

John J Densmore1, Michael E Williams

  • 1Division of Hematology/Oncology, University of Virginia Health System, Box 800716, Charlottesville, VA 22908, USA. jjd2q@virginia.edu

Current Treatment Options in Oncology
|August 29, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synthetic lethality of MCL-1 inhibition and CAR-T therapy in aggressive B-cell lymphoma.

Leukemia·2026
Same author

Bridging the Gap: Pirtobrutinib for Treatment-Naïve Chronic Lymphatic Leukemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Targeting persister cells: proactively overcoming therapy resistance in aggressive B cell lymphomas.

Trends in cancer·2026
Same author

Optimizing mesenchymal stem cell therapy: from isolation to GMP-compliant expansion for clinical application.

BMC molecular and cell biology·2025
Same author

Long-Term Follow-Up of the RESORT Study (E4402): A Randomized Phase III Comparison of Two Different Rituximab Dosing Strategies for Low-Tumor Burden Follicular Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2024
Same author

In-depth cellular and humoral dynamics of the response to COVID-19 vaccine booster in patients with chronic B-cell neoplasms.

Blood cancer journal·2023
Same journal

Interaction between Regulated Cell Death Pathways and Core Cellular Processes: Unraveling the Molecular Mechanisms of Cardiotoxicity of Antitumor Drugs.

Current treatment options in oncology·2026
Same journal

Advances in Immunotherapy for Breast Cancer: Up-to-date Strategies of Immune Checkpoint Inhibitors and Therapeutic Vaccines.

Current treatment options in oncology·2026
Same journal

Recent Advances in Neoadjuvant Treatment of Anaplastic Thyroid Carcinoma: A Narrative Review.

Current treatment options in oncology·2026
Same journal

The Immunological Landscape of the Tumor Microenvironment: Implications for Immunotherapy of Unresectable and Metastatic Soft Tissue Sarcomas.

Current treatment options in oncology·2026
Same journal

Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer.

Current treatment options in oncology·2026
Same journal

Emerging Applications of CAR-T Cell Therapy in Overcoming Resistance and Expanding Targets in Hematologic Malignancies: Insights from Recent Research.

Current treatment options in oncology·2026
See all related articles

Mantle cell lymphoma, an aggressive non-Hodgkin's lymphoma, is currently incurable. While treatments show initial response, the disease often progresses, highlighting the need for clinical trials and improved therapeutic strategies.

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin's lymphoma.
  • Current chemotherapeutic approaches offer limited long-term survival, with a median survival of approximately 3 years.
  • There is no established standard treatment protocol for MCL.

Purpose of the Study:

  • To review current treatment strategies for mantle cell lymphoma.
  • To evaluate the efficacy of various chemotherapy regimens, stem cell transplantation, and novel agents.
  • To emphasize the importance of clinical trial enrollment for patients with MCL.

Main Methods:

  • Review of existing literature on MCL treatment.
  • Analysis of response rates and survival data for different therapeutic interventions.

Related Experiment Videos

  • Comparison of outcomes for chemotherapy, high-dose therapy with stem cell transplantation, and other agents.

    • Main Results:

    • Standard chemotherapy regimens (e.g., CVP, CHOP) achieve 50-70% response rates but disease progression is common.
    • Intensive combination chemotherapy may prolong time to progression.
    • High-dose therapy with autologous stem cell transplantation may improve survival but not necessarily time to progression.
    • Allogeneic stem cell transplantation shows promise in select young patients.
    • Agents like rituximab, fludarabine, and cladribine demonstrate activity but not superior survival benefits over combination chemotherapy.

    Conclusions:

    • Mantle cell lymphoma remains an incurable malignancy with current treatments.
    • Clinical trial participation is crucial for patients with MCL.
    • While various intensive therapies exist, none have definitively improved overall survival compared to standard chemotherapy, underscoring the need for novel therapeutic development.